# US 2019/0315853 A1 · Antibodies to il-15

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315853 A1
- Document ID: US20190315853A1
- Status: Published application
- Kind: A1
- Application number: 16/421,509
- Filed: 2019-05-24
- Published: 2019-10-17
- Earliest claimed: 2014-07-02
- Assignees: Calypso Biotech SA
- Applicants: Calypso Biotech SA
- Inventors: ALAIN VICARI; OLIVIER LEGER
- Web page: https://patentgrep.com/patent/US20190315853A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/6869: {Interleukin}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/5443: IL-15
- G01N 2333/7155: for interleukins [IL]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to antibodies binding IL-15, in particular humanized antibodies. In particular, the anti-IL-15 antibodies according to the invention are able to neutralize IL-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens.

## Claims

### Claim 1

A method of preventing and/or treating an IL-15 related disease or disorder comprising administering in a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof comprising:
(1) a heavy chain variable region of SEQ ID NO: 5 or any variant thereof wherein 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acids of said sequence are substituted by a different amino acid, and
(2) a light chain variable region of SEQ ID NO: 24 or any variant thereof wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of said sequence are substituted by a different amino acid,
or an antigen-binding fragment thereof;
or a pharmaceutical composition thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the IL-15 related disease or disorder is selected from an autoimmune disease, an inflammatory disorder, a malignancy, a metabolic condition, an infectious disease caused by parasitic, viral or bacterial pathogens, amyloid related disorders and/or a transplant rejection.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the IL-15 related disease or disorder is an autoimmune disorder.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the IL-15 related disease or disorder is eosinophilic esophagitis.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the IL-15 related disease or disorder is selected from rheumatoid arthritis, psoriasis, celiac disease, refractory celiac disease, sarcoidosis, inflammatory bowel disease, hepatitis C-induced liver diseases, multiple sclerosis, auto-immune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary atresia, alopecia areata, transplant rejection, inflammatory diseases of the central nervous system, Alzheimer's disease, viral infections, and Hantaan viral infections and eosinophilic esophagitis.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the IL-15 related disease or disorder is celiac disease.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the IL-15 related disease or disorder is alopecia areata.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said antibody or antigen-binding fragment thereof is to be administered in combination with a co-agent useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens, or a compound lowering intestinal inflammation, and/or protecting intestinal mucosa, and/or lowering the immune reactivity of gluten peptides, and/or modifying the gut microbiota.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the antibody or antigen-binding fragment thereof, comprises:
(1) a heavy chain variable region of SEQ ID NO: 5 or any variant thereof having at least 95% identity with SEQ ID NO: 5, and
(2) a light chain variable region of SEQ ID NO: 24 or any variant thereof having at least 95% identity with SEQ ID NO: 24,
or an antigen-binding fragment thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the antibody is a humanized antibody.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the said antibody or antigen-binding fragment comprises:
(1) a heavy chain variable region of SEQ ID NO: 5 or any variant thereof wherein 1, 2, 3, 4, 5 or 6 amino acids selected among:
(i) arginine (R) at position H3 (VH RH3), methionine (M) at position H5 (VH MH5), alanine (A) at position H6 (VH AH6), alanine (A) at position H49 (VH AH49), within the heavy chain variable framework region, and/or
(ii) aspartic acid (D) at position H61 (VH DH61), serine (S) at position H62 (VH SH62), within the heavy chain CDR2, and/or
(iii) methionine (M) at position H98 (VH MH98), tryptophan (W) at position H100C (VH WH100C), methionine (M) at position H100E (VH MI-1100E), within the heavy chain CDR3,
are substituted by a different amino acid, and
(2) a light chain variable region of SEQ ID NO: 24 or any variant thereof wherein 1, 2, 3, or 4 amino acids selected among:
(i) tyrosine (Y) at position L36 (VL YL36), leucine (L) at position L46 (VL LL46), within the light chain variable framework region, and/or
(ii) aspartic acid (D) at position L91 (VL DL91), serine (S) at position L92 (VL SL92), within the light chain CDR3,
are substituted by a different amino acid.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the said antibody or antigen-binding fragment thereof comprises:
(1) said variant of SEQ ID NO: 5 has the amino acid sequence of SEQ ID NO: 5 except that:
(i) VH RH3 is substituted by glutamine (Q), and/or VH MH5 is substituted by valine (V), and/or VH AH6 is substituted by glutamic acid (E), and/or VH AH49 is substituted by serine (S), and/or
(ii) VH DH61 is substituted by glutamic acid (E), and/or VH SH62 is substituted by threonine (T), and/or
(iii) VH MH98 is substituted by leucine (L), phenylalanine (F), isoleucine (I), or alanine (A), and/or VH WH100C is substituted by tyrosine (Y), phenylalanine (F), or alanine (A), and/or VH MI-1100E is substituted by leucine (L), phenylalanine (F), or isoleucine (I), and/or
(2) said variant of SEQ ID NO: 24 has the amino acid sequence of SEQ ID NO: 24 except that:
(i) VL YL36 is substituted by phenylalanine (F), and/or VL LL46 is substituted by arginine (R), and/or
(ii) VL DL91 is substituted by glutamic acid (E), and/or VL SL92 is substituted by threonine (T).

### Claim 13 (depends on 1)

The method according to claim 1, wherein the said antibody or antigen-binding fragment thereof comprises:
(1) a heavy chain variable region of amino acid sequence of SEQ ID NO: 5 except that:
(i) VH RH3 is substituted by glutamine (Q), and/or VH MH5 is substituted by valine (V), and/or VH AH6 is substituted by glutamic acid (E), and/or
(ii) VH SH62 is substituted by threonine (T), and/or
(iii) VH WH100C is substituted by tyrosine (Y), and
(2) a light chain variable region of amino acid sequence of SEQ ID NO: 24.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the said antibody or antigen-binding fragment thereof comprises:
(1) a heavy chain variable region selected from: SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 21, and SEQ ID NO: 5, and
(2) a light chain variable region of SEQ ID NO: 24.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the said antibody or antigen-binding fragment thereof comprises a heavy chain variable region of SEQ ID NO: 6 and a light chain variable region of SEQ ID NO: 24.
